Mar 27 |
Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer
|
Mar 27 |
Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium
|
Mar 25 |
Dyne Therapeutics appoints John Cox CEO
|
Mar 25 |
Dyne Therapeutics Announces CEO Transition
|
Mar 13 |
Dyne Therapeutics to Present at Stifel 2024 Virtual CNS Days
|
Mar 7 |
Dyne Therapeutics Inc (DYN) Reports Encouraging Clinical Data and Financial Growth for Q4 and ...
|
Mar 5 |
Dyne: H2 2024 Muscle Disease Data Could Boost Value
|
Mar 5 |
Dyne Therapeutics files mixed securities shelf
|
Mar 5 |
Dyne Therapeutics GAAP EPS of -$1.09 misses by $0.17
|
Mar 5 |
Dyne Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
|